We have been very clear, and it is our internal rule, that whenever we have an inspection and whenever we have exchanges of correspondence regarding our manufacturing plant in Boucherville, whether it's with the Canadian or the U.S. authorities, we share and exchange....
So when we received the warning letter, we were very clear and transparent with Health Canada that we had received a warning letter. At that time, a warning letter would not immediately create a reduced production output.
The way the warning letter works...we had three weeks to respond to the warning letter, which we did. Thereafter, we realized that the production output was going to be reduced. We took this situation seriously, and at all times our decision was based on minimizing patient disruption. That's why we worked on the most medically necessary products.